Schwab Charles Investment Management Inc. increased its position in shares of Retrophin, Inc. (NASDAQ:RTRX) by 24.5% during the first quarter, Holdings Channel reports. The fund owned 204,621 shares of the biopharmaceutical company’s stock after buying an additional 40,330 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Retrophin were worth $3,778,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC increased its position in shares of Retrophin by 783.3% in the first quarter. Renaissance Technologies LLC now owns 364,800 shares of the biopharmaceutical company’s stock worth $6,734,000 after buying an additional 323,500 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Retrophin by 53.7% in the first quarter. Dimensional Fund Advisors LP now owns 553,702 shares of the biopharmaceutical company’s stock worth $10,221,000 after buying an additional 193,432 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Retrophin by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,509,539 shares of the biopharmaceutical company’s stock worth $27,866,000 after buying an additional 102,833 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Retrophin by 196.0% in the first quarter. TIAA CREF Investment Management LLC now owns 636,545 shares of the biopharmaceutical company’s stock worth $11,751,000 after buying an additional 421,515 shares during the last quarter. Finally, Teachers Advisors LLC increased its position in shares of Retrophin by 25.3% in the first quarter. Teachers Advisors LLC now owns 367,274 shares of the biopharmaceutical company’s stock worth $6,780,000 after buying an additional 74,186 shares during the last quarter.

Shares of Retrophin, Inc. (RTRX) traded up 2.27% during mid-day trading on Wednesday, reaching $23.01. 56,083 shares of the company traded hands. The firm has a 50 day moving average of $20.04 and a 200-day moving average of $19.08. The stock’s market capitalization is $883.24 million. Retrophin, Inc. has a 52 week low of $15.55 and a 52 week high of $24.57.

Retrophin (NASDAQ:RTRX) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.10. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The company had revenue of $38.80 million during the quarter, compared to analysts’ expectations of $37.36 million. During the same quarter last year, the firm earned $0.07 EPS. Retrophin’s revenue for the quarter was up 16.5% on a year-over-year basis. On average, equities research analysts expect that Retrophin, Inc. will post ($1.11) EPS for the current fiscal year.

WARNING: “Retrophin, Inc. (RTRX) Shares Bought by Schwab Charles Investment Management Inc.” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/retrophin-inc-rtrx-shares-bought-by-schwab-charles-investment-management-inc/1495560.html.

A number of research analysts have issued reports on the stock. ValuEngine raised shares of Retrophin from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. TheStreet raised shares of Retrophin from a “d” rating to a “c-” rating in a research report on Friday, May 12th. Finally, Zacks Investment Research downgraded shares of Retrophin from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Retrophin presently has an average rating of “Buy” and an average price target of $32.25.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.